首页 > 市场调查报告书 > 製药

再生医学细胞疗法

全球 T 细胞疗法市场研究报告 - 2024 年至 2032 年产业分析、规模、份额、成长、趋势和预测

市场调查报告书

商品编码

1408996

全球 T 细胞疗法市场研究报告 - 2024 年至 2032 年产业分析、规模、份额、成长、趋势和预测

Global T-Cell Therapies Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年01月01日 | 出版商:

Value Market Research | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

全球 T 细胞治疗市场需求预计将从 2022 年的 24.8 亿美元增至 2030 年的近 295.1 亿美元，2023-2030 年研究期间CAGR为 36.28%。

T 细胞疗法涉及使用 T 细胞（一种白血球）来治疗各种疾病，特别是某些类型的癌症和免疫相关疾病。 T 细胞在免疫系统中至关重要，因为它们可以识别并消除异常或受感染的细胞。 T 细胞疗法利用并增强人体的自然防御机制来瞄准和破坏特定细胞。

市场动态

T 细胞疗法市场是由这些疗法的革命性潜力所推动的，特别是在癌症治疗方面。癌症盛行率的增加以及对更精确、更有效的治疗的需求推动了 T 细胞疗法的采用，例如 CAR-T 细胞疗法。生物技术和基因工程的进步发挥着至关重要的作用，使 T 细胞的基因修饰能够增强对癌细胞的靶向作用。正面的临床结果和已证实的疗效有助于增强医疗保健专业人员和患者的信心，进一步促进市场的扩张。研究和开发方面的合作和投资加速了进展，从而开发出新的和改进的 T 细胞疗法。监管批准和支援框架确保了可及性和商业化，从而加强了市场的成长轨迹。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具也对全球 T 细胞疗法市场的各个细分市场进行了包容性评估。 T 细胞疗法产业的成长和趋势为本研究提供了整体方法。

区域分析

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲 T 细胞治疗市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。 T细胞疗法市场的主要参与者包括诺华公司、默克公司、吉利德科学公司、TCR2 Therapeutics Inc.、Bluebird Bio Inc.、Sorrento Therapeutics、Fate Therapeutics、辉瑞公司、安进公司、新基公司。本节包含竞争格局的整体视图，包括各种策略发展，例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

区域展望
介绍
北美销售分析
- 概览、历史与预测资料销售分析
- 北美按细分市场销售分析
- 北美按国家销售分析
- 美国销售分析
- 加拿大销售分析
- 墨西哥销售分析
欧洲销售分析
- 概览、历史与预测资料销售分析
- 欧洲按细分市场销售分析
- 欧洲按国家销售分析
- 英国销售分析
- 法国销售分析
- 德国销售分析
- 义大利销售分析
- 俄罗斯销售分析
- 欧洲其他地区销售分析
亚太地区销售分析
- 概览、历史与预测资料销售分析
- 亚太地区按细分市场销售分析
- 亚太地区国家/地区销售分析
- 中国销售分析
- 印度销售分析
- 日本销售分析
- 韩国销售分析
- 澳洲销售分析
- 东南亚销售分析
- 亚太地区其他地区销售分析
拉丁美洲销售分析
- 概览、历史与预测资料销售分析
- 拉丁美洲按细分市场销售分析
- 拉丁美洲按国家销售分析
- 巴西销售分析
- 阿根廷销售分析
- 秘鲁销售分析
- 智利销售分析
- 拉丁美洲其他地区销售分析
中东和非洲销售分析
- 概览、历史与预测资料销售分析
- 中东和非洲按细分市场销售分析
- 中东和非洲国家销售分析
- 沙乌地阿拉伯销售分析
- 阿联酋销售分析
- 以色列销售分析
- 南非销售分析
- 中东其他地区和非洲销售分析

第 8 章：T 细胞疗法公司的竞争格局

T细胞疗法市场竞争
伙伴关係/协作/协议
併购
新产品发布
其他发展

第 9 章：公司简介

顶级公司市占率分析
市场集中度
Novartis AG

公司简介
公司收入
产品
最近的发展

Merck KGaA

公司简介
公司收入
产品
最近的发展

Gilead Sciences Inc.

公司简介
公司收入
产品
最近的发展

TCR2 Therapeutics Inc.

公司简介
公司收入
产品
最近的发展

Bluebird Bio Inc.

公司简介
公司收入
产品
最近的发展

Sorrento Therapeutics

公司简介
公司收入
产品
最近的发展

Fate Therapeutics

公司简介
公司收入
产品
最近的发展

Pfizer Inc.

公司简介
公司收入
产品
最近的发展

Amgen

公司简介
公司收入
产品
最近的发展

Celgene Corporation

公司简介
公司收入
产品
最近的发展

注意 - 在公司概况中，财务详细资讯和近期发展视情况而定，或者如果是私人公司，则可能不包括在内

简介目录图表

Product Code: VMR112113250

The global demand for T-Cell Therapies Market is presumed to reach the market size of nearly USD 29.51 BN by 2030 from USD 2.48 BN in 2022 with a CAGR of 36.28% under the study period 2023 - 2030.

T-cell therapies involve the use of T cells, a type of white blood cell, to treat various medical conditions, particularly certain types of cancers and immune-related disorders. T-cells are crucial in the immune system as these recognize and eliminate abnormal or infected cells. T-cell therapies harness and enhance the body's natural defense mechanisms to target and destroy specific cells.

MARKET DYNAMICS

The T-cell therapies market is driven by the revolutionary potential of these therapies, particularly in cancer treatment. The increasing cancer prevalence and the demand for more precise and effective treatments propel the adoption of T-cell therapies, such as CAR-T cell therapy. Advancements in biotechnology and genetic engineering play a crucial role, enabling the genetic modification of T cells for enhanced targeting of cancer cells. Positive clinical outcomes and demonstrated efficacy contribute to growing confidence among healthcare professionals and patients, further fostering the market's expansion. Collaborations and investments in research and development accelerate progress, leading to the development of new and improved T-cell therapies. Regulatory approvals and supportive frameworks ensure accessibility and commercialization, reinforcing the market's growth trajectory.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of t-cell therapies. The growth and trends of t-cell therapies industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the t-cell therapies market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Therapy Type

CART-Cell Therapy
T Cell Receptor (TCR)-Based
Tumor Infiltrating Lymphocytes (TIL)-Based

By Indication

Hematologic Malignancies (Lymphoma, Leukemia, Myeloma)
Solid Tumors (Melanoma, Brain & Central Nervous System, Liver Cancer, Others)
Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the T-Cell Therapies market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the T-Cell Therapies market include Novartis AG, Merck KGaA, Gilead Sciences Inc., TCR2 Therapeutics Inc., Bluebird Bio Inc., Sorrento Therapeutics, Fate Therapeutics, Pfizer Inc., Amgen, Celgene Corporation. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . T-CELL THERAPIES - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Therapy Type
- 3.7.2 Market Attractiveness Analysis By Indication
- 3.7.3 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . GLOBAL T-CELL THERAPIES MARKET ANALYSIS BY THERAPY TYPE

5.1 Overview by Therapy Type
5.2 Historical and Forecast Data
5.3 Analysis by Therapy Type
5.4 CAR T-cell Therapy Historic and Forecast Sales by Regions
5.5 T Cell Receptor (TCR)-based Historic and Forecast Sales by Regions
5.6 Tumor Infiltrating Lymphocytes (TIL)-based Historic and Forecast Sales by Regions

6 . GLOBAL T-CELL THERAPIES MARKET ANALYSIS BY INDICATION

6.1 Overview by Indication
6.2 Historical and Forecast Data
6.3 Analysis by Indication
6.4 Hematologic Malignancies (Lymphoma, Leukemia, Myeloma) Historic and Forecast Sales by Regions
6.5 Solid Tumors (Melanoma, Brain & Central Nervous System, Liver Cancer, Others) Historic and Forecast Sales by Regions
6.6 Others Historic and Forecast Sales by Regions

7 . GLOBAL T-CELL THERAPIES MARKET ANALYSIS BY GEOGRAPHY

7.1. Regional Outlook
7.2. Introduction
7.3. North America Sales Analysis
- 7.3.1. Overview, Historic and Forecast Data Sales Analysis
- 7.3.2. North America By Segment Sales Analysis
- 7.3.3. North America By Country Sales Analysis
- 7.3.4. United State Sales Analysis
- 7.3.5. Canada Sales Analysis
- 7.3.6. Mexico Sales Analysis
7.4. Europe Sales Analysis
- 7.4.1. Overview, Historic and Forecast Data Sales Analysis
- 7.4.2. Europe by Segment Sales Analysis
- 7.4.3. Europe by Country Sales Analysis
- 7.4.4. United Kingdom Sales Analysis
- 7.4.5. France Sales Analysis
- 7.4.6. Germany Sales Analysis
- 7.4.7. Italy Sales Analysis
- 7.4.8. Russia Sales Analysis
- 7.4.9. Rest Of Europe Sales Analysis
7.5. Asia Pacific Sales Analysis
- 7.5.1. Overview, Historic and Forecast Data Sales Analysis
- 7.5.2. Asia Pacific by Segment Sales Analysis
- 7.5.3. Asia Pacific by Country Sales Analysis
- 7.5.4. China Sales Analysis
- 7.5.5. India Sales Analysis
- 7.5.6. Japan Sales Analysis
- 7.5.7. South Korea Sales Analysis
- 7.5.8. Australia Sales Analysis
- 7.5.9. South East Asia Sales Analysis
- 7.5.10. Rest Of Asia Pacific Sales Analysis
7.6. Latin America Sales Analysis
- 7.6.1. Overview, Historic and Forecast Data Sales Analysis
- 7.6.2. Latin America by Segment Sales Analysis
- 7.6.3. Latin America by Country Sales Analysis
- 7.6.4. Brazil Sales Analysis
- 7.6.5. Argentina Sales Analysis
- 7.6.6. Peru Sales Analysis
- 7.6.7. Chile Sales Analysis
- 7.6.8. Rest of Latin America Sales Analysis
7.7. Middle East & Africa Sales Analysis
- 7.7.1. Overview, Historic and Forecast Data Sales Analysis
- 7.7.2. Middle East & Africa by Segment Sales Analysis
- 7.7.3. Middle East & Africa by Country Sales Analysis
- 7.7.4. Saudi Arabia Sales Analysis
- 7.7.5. UAE Sales Analysis
- 7.7.6. Israel Sales Analysis
- 7.7.7. South Africa Sales Analysis
- 7.7.8. Rest Of Middle East And Africa Sales Analysis

8 . COMPETITIVE LANDSCAPE OF THE T-CELL THERAPIES COMPANIES

8.1. T-Cell Therapies Market Competition
8.2. Partnership/Collaboration/Agreement
8.3. Merger And Acquisitions
8.4. New Product Launch
8.5. Other Developments

9 . COMPANY PROFILES OF T-CELL THERAPIES INDUSTRY

9.1. Top Companies Market Share Analysis
9.2. Market Concentration Rate
9.3. Novartis AG
- 9.3.1. Company Overview
- 9.3.2. Company Revenue
- 9.3.3. Products
- 9.3.4. Recent Developments
9.4. Merck KGaA
- 9.4.1. Company Overview
- 9.4.2. Company Revenue
- 9.4.3. Products
- 9.4.4. Recent Developments
9.5. Gilead Sciences Inc.
- 9.5.1. Company Overview
- 9.5.2. Company Revenue
- 9.5.3. Products
- 9.5.4. Recent Developments
9.6. TCR2 Therapeutics Inc.
- 9.6.1. Company Overview
- 9.6.2. Company Revenue
- 9.6.3. Products
- 9.6.4. Recent Developments
9.7. Bluebird Bio Inc.
- 9.7.1. Company Overview
- 9.7.2. Company Revenue
- 9.7.3. Products
- 9.7.4. Recent Developments
9.8. Sorrento Therapeutics
- 9.8.1. Company Overview
- 9.8.2. Company Revenue
- 9.8.3. Products
- 9.8.4. Recent Developments
9.9. Fate Therapeutics
- 9.9.1. Company Overview
- 9.9.2. Company Revenue
- 9.9.3. Products
- 9.9.4. Recent Developments
9.10. Pfizer Inc.
- 9.10.1. Company Overview
- 9.10.2. Company Revenue
- 9.10.3. Products
- 9.10.4. Recent Developments
9.11. Amgen
- 9.11.1. Company Overview
- 9.11.2. Company Revenue
- 9.11.3. Products
- 9.11.4. Recent Developments
9.12. Celgene Corporation
- 9.12.1. Company Overview
- 9.12.2. Company Revenue
- 9.12.3. Products
- 9.12.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

简介目录图表

LIST OF TABLES

Market Snapshot
Drivers : Impact Analysis
Restraints : Impact Analysis
List of Raw Material
List of Raw Material Manufactures
List of Potential Buyers
Analysis by Therapy Type (USD MN)
CAR T-cell Therapy Market Sales by Geography (USD MN)
T Cell Receptor (TCR)-based Market Sales by Geography (USD MN)
Tumor Infiltrating Lymphocytes (TIL)-based Market Sales by Geography (USD MN)
Analysis Market by Indication (USD MN)
Hematologic Malignancies (Lymphoma, Leukemia, Myeloma) Market Sales by Geography (USD MN)
Solid Tumors (Melanoma, Brain & Central Nervous System, Liver Cancer, Others) Market Sales by Geography (USD MN)
Others Market Sales by Geography (USD MN)
Global T-Cell Therapies Market Sales by Geography (USD MN)
North America Market Analysis (USD MN)
United State Market Analysis (USD MN)
Canada Market Analysis (USD MN)
Mexico Market Analysis (USD MN)
Europe Market Analysis (USD MN)
Europe Market Estimate by Country (USD MN)
United Kingdom Market Analysis (USD MN)
France Market Analysis (USD MN)
Germany Market Analysis (USD MN)
Italy Market Analysis (USD MN)
Russia Market Analysis (USD MN)
Spain Market Analysis (USD MN)
Rest of Europe Market Analysis (USD MN)
Asia Pacific Market Analysis (USD MN)
China Market Analysis (USD MN)
Japan Market Analysis (USD MN)
India Market Analysis (USD MN)
South Korea Market Analysis (USD MN)
Australia Market Analysis (USD MN)
South East Asia Market Analysis (USD MN)
Rest of Asia Pacific Market Analysis (USD MN)
Latin America Market Analysis (USD MN)
Brazil Market Analysis (USD MN)
Argentina Market Analysis (USD MN)
Peru Market Analysis (USD MN)
Chile Market Analysis (USD MN)
Rest of Latin America Market Analysis (USD MN)
Middle East & Africa Market Analysis (USD MN)
Saudi Arabia Market Analysis (USD MN)
UAE Market Analysis (USD MN)
Israel Market Analysis (USD MN)
South Africa Market Analysis (USD MN)
Rest of Middle East and Africa Market Analysis (USD MN)
Partnership/Collaboration/Agreement
Mergers And Acquisition

LIST OF FIGURES

Research Scope of T-Cell Therapies Report
Market Research Process
Market Research Methodology
Global T-Cell Therapies Market Size, by Region (USD MN)
Porters Five Forces Analysis
Market Attractiveness Analysis by Therapy Type
Market Attractiveness Analysis by Indication
Market Attractiveness Analysis by Region
Value Chain Analysis
Global Market Analysis by Therapy Type (USD MN)
CAR T-cell Therapy Market Sales by Geography (USD MN)
T Cell Receptor (TCR)-based Market Sales by Geography (USD MN)
Tumor Infiltrating Lymphocytes (TIL)-based Market Sales by Geography (USD MN)
Global Market Analysis by Indication (USD MN)
Hematologic Malignancies (Lymphoma, Leukemia, Myeloma) Market Sales by Geography (USD MN)
Solid Tumors (Melanoma, Brain & Central Nervous System, Liver Cancer, Others) Market Sales by Geography (USD MN)
Others Market Sales by Geography (USD MN)
Global Market Sales (USD MN)
North America Market Sales (USD MN)
Europe Market Sales (USD MN)
Asia Pacific Market Sales (USD MN)
Latin America Market Sales (USD MN)
Middle East & Africa Market Sales (USD MN)
Recent Development in Industry
Top Companies Market Share Analysis